<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="2f9c7d6f-7f0f-f9dd-e063-6294a90abf59"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use AXUMIN safely and effectively. See full prescribing information for AXUMIN.
 <br/>
      <br/>
AXUMIN (fluciclovine F 18) injection, for intravenous use
 <br/>
Initial U.S. Approval: 2016
</title>
   <effectiveTime value="20250305"/>
   <setId root="389a502e-a7d5-43dd-b6bf-f022ff23f3b9"/>
   <versionNumber value="16"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="219742530"/>
            <name>Blue Earth Diagnostics</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="004201823"/>
                        <name>PETNET Solutions, Inc. (Philadelphia)</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69932-001" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="018432646"/>
                        <name>The University of Utah DBA Cyclotron Radiochemistry Lab, Huntsman Cancer Institute</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69932-001" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="026659644"/>
                        <name>PETNET Solutions, Inc.(Seattle)</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69932-001" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="078575260"/>
                        <name>PETNET Solutions, Inc. (Denver)</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69932-001" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="111110727"/>
                        <name>PETNET Solutions, Inc. (Jacksonville)</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69932-001" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="123562576"/>
                        <name>PETNET Solutions, Inc. (Portland)</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69932-001" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="125764907"/>
                        <name>PETNET Solutions, Inc. (San Antonio)</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69932-001" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="128523862"/>
                        <name>PETNET Solutions, Inc. (Columbia)</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69932-001" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="134146484"/>
                        <name>PETNET Solutions, Inc. (New Orleans)</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69932-001" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="515048908"/>
                        <name>GE Healthcare AS</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C82401" displayName="api manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69932-001" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="603833208"/>
                        <name>PETNET Solutions, Inc. (Phoenix)</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69932-001" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="621380547"/>
                        <name>P.E.T.NET Houston, LLC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69932-001" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="788930480"/>
                        <name>PETNET Solutions, Inc. (Tampa)</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69932-001" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="796129646"/>
                        <name>PETNET Solutions, Inc. (Hackensack)</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69932-001" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="798884966"/>
                        <name>PETNET Solutions, Inc. (Tulsa)</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69932-001" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="799246256"/>
                        <name>PETNET Solutions, Inc. (Dallas)</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69932-001" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="840517945"/>
                        <name>PETNET Solutions, Inc. (Nashville)</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69932-001" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="961592982"/>
                        <name>PETNET Solutions, Inc. (Atlanta)</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69932-001" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="961593220"/>
                        <name>PETNET Solutions, Inc. (Cincinnati)</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69932-001" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="961593337"/>
                        <name>PETNET Solutions, Inc. (Louisville)</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69932-001" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="961597072"/>
                        <name>PETNET Solutions, Inc. (Winston-Salem)</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69932-001" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="961597213"/>
                        <name>PETNET Solutions, Inc. (Cleveland)</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69932-001" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="018537881"/>
                        <name>PETNET Solutions, Inc. (Albany)</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69932-001" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="078575242"/>
                        <name>PETNET Solutions, Inc. (Sacramento)</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69932-001" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="154173350"/>
                        <name>PETNET Solutions, Inc. (Little Rock)</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69932-001" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="961597122"/>
                        <name>PETNET Solutions, Inc. (Boston)</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69932-001" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="079262099"/>
                        <name>PETNET Solutions, Inc. (Loma Linda)</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69932-001" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="080547824"/>
                        <name>PETNET Solutions, Inc. (San Francisco)</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69932-001" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="102326340"/>
                        <name>PETNET Solutions, Inc. (Kansas City)</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69932-001" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="798775214"/>
                        <name>PETNET Solutions, Inc. (Spokane)</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69932-001" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="961593386"/>
                        <name>PETNET Solutions, Inc. (Detroit)</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69932-001" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="961682551"/>
                        <name>PETNET Solutions, Inc. (Albuquerque)</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69932-001" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="965557486"/>
                        <name>PETNET Solutions, Inc. (Minneapolis)</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69932-001" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="968897954"/>
                        <name>PETNET Solutions, Inc. (Charlottesville)</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69932-001" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="117843428"/>
                        <name>PETNET Solutions Inc (South Florida)</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69932-001" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="961597221"/>
                        <name>PETNET Solutions Inc (Las Vegas)</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69932-001" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="118120165"/>
                        <name>PETNET Solutions Inc (Chicago 2)</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69932-001" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="033883716"/>
                        <name>PETNET Solutions Inc. (Culver City)</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69932-001" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="2f9c3475-ad2d-cd28-e063-6294a90a413f"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250305"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="69932-001" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Axumin</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Fluciclovine F-18</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="1Q73Q2JULR" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CITRATE, UNSPECIFIED FORM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mCi" value="221"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="38R1Q0L1ZE" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FLUCICLOVINE F-18</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="38R1Q0L1ZE" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>FLUCICLOVINE F-18</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="69932-001-30" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43210" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, MULTI-DOSE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20160527"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="50" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="69932-001-50" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43210" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, MULTI-DOSE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20160527"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA208054" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20160527"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="s1">
               <id root="2f9c7d6f-7f10-f9dd-e063-6294a90abf59"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Axumin is indicated for positron emission tomography (PET) in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment.</paragraph>
               </text>
               <effectiveTime value="20210528"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Axumin is a radioactive diagnostic agent indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment (
 
    <linkHtml href="#s1">1</linkHtml>).

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s2">
               <id root="2f9c7d6f-7f11-f9dd-e063-6294a90abf59"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20210528"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Use appropriate radiation safety handling measures (
  
     <linkHtml href="#s3">2.1</linkHtml>).
 
    </item>
                           <item>Aseptically withdraw Axumin from its container and administer 370 MBq (10 mCi) as a bolus intravenous injection. (
  
     <linkHtml href="#s4">2.2</linkHtml>).
 
    </item>
                           <item>Initiate imaging 3 minutes to 5 minutes after administration. Scanning should start from mid-thigh and proceed to base of skull, with a total scan time of approximately 20 minutes to 30 minutes (
  
     <linkHtml href="#s6">2.4</linkHtml>).
 
    </item>
                           <item>The (radiation absorbed) effective dose associated with 370 MBq (10 mCi) of injected activity of Axumin is approximately 8 mSv (0.8 rem) in an adult (
  
     <linkHtml href="#s8">2.6</linkHtml>).
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s3">
                     <id root="2f9c7d6f-7f12-f9dd-e063-6294a90abf59"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Radiation Safety - Drug Handling</title>
                     <text>
                        <paragraph>Axumin is a radioactive drug and should be handled with appropriate safety measures to minimize radiation exposure during administration [see
 
  <content styleCode="italics">Warnings and Precautions (
  
   <linkHtml href="#s14">5.3</linkHtml>)
 
  </content>]. Use waterproof gloves and effective shielding, including syringe shields, when handling and administering Axumin.

 </paragraph>
                     </text>
                     <effectiveTime value="20210528"/>
                  </section>
               </component>
               <component>
                  <section ID="s4">
                     <id root="2f9c7d6f-7f13-f9dd-e063-6294a90abf59"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Recommended Dose and Administration Instructions</title>
                     <text>
                        <paragraph>The recommended dose is 370 MBq (10 mCi) administered as an intravenous bolus injection.</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Inspect Axumin visually for particulate matter and discoloration before administration. Do not use the drug if the solution contains particulate matter or is discolored.</item>
                           <item>Use aseptic technique and radiation shielding when withdrawing and administering Axumin.</item>
                           <item>Calculate the necessary volume to administer based on calibration time and date, using a suitably calibrated instrument. The recommended maximum volume of injection of undiluted Axumin is 5mL.</item>
                           <item>Axumin may be diluted with 0.9% Sodium Chloride Injection, USP.</item>
                           <item>After the Axumin injection, administer an intravenous flush of sterile 0.9% Sodium Chloride Injection, USP to ensure full delivery of the dose.</item>
                           <item>Dispose of any unused drug in a safe manner in compliance with applicable regulations.</item>
                        </list>
                     </text>
                     <effectiveTime value="20210528"/>
                  </section>
               </component>
               <component>
                  <section ID="s5">
                     <id root="2f9c7d6f-7f14-f9dd-e063-6294a90abf59"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Patient Preparation Prior to PET Imaging</title>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Advise the patient to avoid any significant exercise for at least one day prior to PET imaging.</item>
                           <item>Advise patients not to eat or drink for at least 4 hours (other than sips of water for taking medications) prior to administration of Axumin.</item>
                           <item>Advise patients to void approximately 30 minutes to 60 minutes prior to administration of Axumin and then refrain from voiding until after the scan has been completed</item>
                        </list>
                     </text>
                     <effectiveTime value="20210528"/>
                  </section>
               </component>
               <component>
                  <section ID="s6">
                     <id root="2f9c7d6f-7f15-f9dd-e063-6294a90abf59"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4 Image Acquisition Guidelines</title>
                     <text>
                        <paragraph>Position the patient supine with arms above the head. Begin PET scanning 3 minutes to 5 minutes after completion of the Axumin injection. It is recommended that image acquisition should start from mid-thigh and proceed to the base of the skull. Typical total scan time is between 20 minutes to 30 minutes.</paragraph>
                     </text>
                     <effectiveTime value="20210528"/>
                  </section>
               </component>
               <component>
                  <section ID="s7">
                     <id root="2f9c7d6f-7f16-f9dd-e063-6294a90abf59"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.5 Image Display and Interpretation</title>
                     <text>
                        <paragraph>Localization of prostate cancer recurrence in sites typical for prostate cancer recurrence is based on fluciclovine F 18 uptake in comparison with tissue background. For small lesions (less than 1cm in diameter) focal uptake greater than blood pool should be considered suspicious for prostate cancer recurrence. For larger lesions, uptake equal to or greater than bone marrow is considered suspicious for prostate cancer recurrence.</paragraph>
                     </text>
                     <effectiveTime value="20210528"/>
                  </section>
               </component>
               <component>
                  <section ID="s8">
                     <id root="2f9c7d6f-7f17-f9dd-e063-6294a90abf59"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.6 Radiation Dosimetry</title>
                     <text>
                        <paragraph>The radiation absorbed doses estimated for adult patients following intravenous injection of Axumin are shown in
 
  <linkHtml href="#t1">Table 1</linkHtml>. Values were calculated from human biodistribution data using OLINDA/EXM (Organ Level Internal Dose Assessment/Exponential Modeling) software.

 </paragraph>
                        <paragraph>The (radiation absorbed) effective dose resulting from the administration of the recommended activity of 370 MBq of Axumin is 8 mSv. For an administered activity of 370 MBq (10 mCi), the highest-magnitude radiation doses are delivered to the pancreas, cardiac wall, and uterine wall: 38 mGy, 19 mGy, and 17 mGy, respectively. If a CT scan is simultaneously performed as part of the PET procedure, exposure to ionizing radiation will increase in an amount dependent on the settings used in the CT acquisition.</paragraph>
                        <table ID="t1" width="100%">
                           <caption>Table 1: Estimated Radiation Absorbed Doses in Various Organs/Tissues in Adults who Received Axumin</caption>
                           <col width="33.650%" align="left"/>
                           <col width="66.350%" align="left"/>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode="Toprule Botrule Lrule Rrule" valign="middle">
                                    <content styleCode="bold">Organ/Tissue</content>
                                 </td>
                                 <td align="center" styleCode="Toprule Botrule Rrule" valign="middle">
                                    <content styleCode="bold">Mean Absorbed Dose per Unit Administered Activity (microGy/MBq)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Adrenal glands</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">16</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Brain</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">9</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Breasts</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">14</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Gallbladder wall</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">17</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Lower large intestine wall</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">12</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Small intestine wall</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">13</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Stomach wall</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">14</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Upper large intestine wall</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">13</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Heart wall</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">52</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Kidneys</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">14</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Liver</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">33</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Lungs</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">34</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Muscle</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">11</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Ovaries</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">13</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Pancreas</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">102</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Red bone marrow</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">25</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Osteogenic cells</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">23</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Skin</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">8</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Spleen</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">24</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Testes</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">17</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Thymus gland</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">12</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Thyroid</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">10</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Urinary bladder wall</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">25</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Uterus</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">45</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Total body</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">13</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">
                                    <content styleCode="bold">Effective dose</content>
                                 </td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">
                                    <content styleCode="bold">22 (microSv/MBq)</content>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20210528"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s9">
               <id root="2f9c7d6f-7f18-f9dd-e063-6294a90abf59"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Injection: supplied as a clear, colorless solution in a 30 mL or 50 mL multiple-dose vial containing 335 MBq/mL to 8,200 MBq/mL (9 mCi/mL to 221 mCi/mL) fluciclovine F 18 at calibration time and date.</paragraph>
               </text>
               <effectiveTime value="20210528"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Injection: clear, colorless solution in a 30 mL or 50 mL multiple-dose vial containing 335 MBq/mL to 8,200 MBq/mL (9 mCi/mL to 221 mCi/mL) fluciclovine F 18 at calibration time and date (
 
    <linkHtml href="#s9">3</linkHtml>).

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s10">
               <id root="2f9c7d6f-7f19-f9dd-e063-6294a90abf59"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>None</paragraph>
               </text>
               <effectiveTime value="20210528"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>None (
 
    <linkHtml href="#s10">4</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s11">
               <id root="2f9c7d6f-7f1a-f9dd-e063-6294a90abf59"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20210528"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Image interpretation errors can occur with Axumin imaging (
  
     <linkHtml href="#s12">5.1</linkHtml>).
 
    </item>
                           <item>Radiation risk: Axumin contributes to a patient's long-term cumulative radiation exposure. Ensure safe handling to protect patients and health care workers from unintentional radiation exposure (
  
     <linkHtml href="#s3">2.1</linkHtml>,
  
     <linkHtml href="#s14">5.3</linkHtml>).
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s12">
                     <id root="2f9c7d6f-7f1b-f9dd-e063-6294a90abf59"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Risk for Image Misinterpretation</title>
                     <text>
                        <paragraph>Image interpretation errors can occur with Axumin PET imaging. A negative image does not rule out the presence of recurrent prostate cancer and a positive image does not confirm the presence of recurrent prostate cancer. The performance of Axumin seems to be affected by PSA levels
 
  <content styleCode="italics">[See Clinical Studies (
  
   <linkHtml href="#s40">14</linkHtml>)]
 
  </content>. Fluciclovine F 18 uptake is not specific for prostate cancer and may occur with other types of cancer and benign prostatic hypertrophy in primary prostate cancer. Clinical correlation, which may include histopathological evaluation of the suspected recurrence site, is recommended.

 </paragraph>
                     </text>
                     <effectiveTime value="20210528"/>
                  </section>
               </component>
               <component>
                  <section ID="s13">
                     <id root="2f9c7d6f-7f1c-f9dd-e063-6294a90abf59"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Hypersensitivity Reactions</title>
                     <text>
                        <paragraph>Hypersensitivity reactions including anaphylaxis may occur in patients who receive Axumin. Emergency resuscitation equipment and personnel should be immediately available.</paragraph>
                     </text>
                     <effectiveTime value="20210528"/>
                  </section>
               </component>
               <component>
                  <section ID="s14">
                     <id root="2f9c7d6f-7f1d-f9dd-e063-6294a90abf59"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Radiation Risks</title>
                     <text>
                        <paragraph>Axumin use contributes to a patient's overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk for cancer. Ensure safe handling to minimize radiation exposure to the patient and health care providers
 
  <content styleCode="italics">[see Dosage and Administration (
  
   <linkHtml href="#s3">2.1</linkHtml>)]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20210528"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s15">
               <id root="2f9c7d6f-7f1e-f9dd-e063-6294a90abf59"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <effectiveTime value="20210528"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most commonly reported adverse reactions are injection site pain, erythema, and dysgeusia (
 
    <linkHtml href="#s16">6.1</linkHtml>).

   </paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Blue Earth Diagnostics, Ltd at 1-855-AXUMIN1 (1-855-298-6461) or FDA at 1-800-FDA-1088 or</content>
                           <content styleCode="underline">www.fda.gov/medwatch</content>.

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s16">
                     <id root="2f9c7d6f-7f1f-f9dd-e063-6294a90abf59"/>
                     <code code="90374-0" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The clinical trial database for Axumin includes data from 877 subjects including 797 males diagnosed with prostate cancer. Most patients received a single administration of Axumin, a small number of subjects (n = 50) received up to five administrations of the drug. The mean administered activity was 370 MBq (range, 163 MBq to 485 MBq).</paragraph>
                        <paragraph>Adverse reactions were reported in ≤1% of subjects during clinical studies with Axumin. The most common adverse reactions were injection site pain, injection site erythema and dysgeusia.</paragraph>
                     </text>
                     <effectiveTime value="20210528"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s17">
               <id root="2f9c7d6f-7f20-f9dd-e063-6294a90abf59"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20210528"/>
               <component>
                  <section ID="s18">
                     <id root="2f9c7d6f-7f21-f9dd-e063-6294a90abf59"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <effectiveTime value="20210528"/>
                     <component>
                        <section ID="s19">
                           <id root="2f9c7d6f-7f22-f9dd-e063-6294a90abf59"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>Axumin is not indicated for use in females and there is no information on the risk of adverse development outcomes in pregnant women or animals with the use of fluciclovine F 18.</paragraph>
                           </text>
                           <effectiveTime value="20210528"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s20">
                     <id root="2f9c7d6f-7f23-f9dd-e063-6294a90abf59"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <effectiveTime value="20210528"/>
                     <component>
                        <section ID="s21">
                           <id root="2f9c7d6f-7f24-f9dd-e063-6294a90abf59"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>Axumin is not indicated for use in females and there is no information of the presence of fluciclovine F 18 in human milk.</paragraph>
                           </text>
                           <effectiveTime value="20210528"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s22">
                     <id root="2f9c7d6f-7f25-f9dd-e063-6294a90abf59"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.3 Pediatric Use</title>
                     <text>
                        <paragraph>Safety and effectiveness have not been established in pediatric patients.</paragraph>
                     </text>
                     <effectiveTime value="20210528"/>
                  </section>
               </component>
               <component>
                  <section ID="s23">
                     <id root="2f9c7d6f-7f26-f9dd-e063-6294a90abf59"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.4 Geriatric Use</title>
                     <text>
                        <paragraph>Of the total number of patients in clinical studies of Axumin, the average age was 66 years with a range of 21 to 90 years. No overall differences in safety or effectiveness were observed between older subjects and younger subjects.</paragraph>
                     </text>
                     <effectiveTime value="20210528"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s24">
               <id root="2f9c7d6f-7f27-f9dd-e063-6294a90abf59"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>In case of overdose of Axumin, encourage patients to maintain hydration and to void frequently to minimize radiation exposure.</paragraph>
               </text>
               <effectiveTime value="20210528"/>
            </section>
         </component>
         <component>
            <section ID="s25">
               <id root="2f9c7d6f-7f28-f9dd-e063-6294a90abf59"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <effectiveTime value="20210528"/>
               <component>
                  <section ID="s26">
                     <id root="2f9c7d6f-7f29-f9dd-e063-6294a90abf59"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>11.1 Chemical Characteristics</title>
                     <text>
                        <paragraph>Axumin contains the fluorine 18 (F 18) labeled synthetic amino acid analog fluciclovine. Fluciclovine F 18 is a radioactive diagnostic agent used with PET imaging. Chemically, fluciclovine F 18 is (1r, 3r)-1-amino-3[
 
  <sup>18</sup>F]fluorocyclobutane-1-carboxylic acid. The molecular weight is 132.1 and the structural formula is:

 </paragraph>
                        <renderMultiMedia ID="f01" referencedObject="mm01"/>
                        <paragraph>Axumin is a sterile, non-pyrogenic, clear, colorless, hyperosmolal (approximately 500 mOsm/kg to 540 mOsm/kg) injection for intravenous use. Each milliliter contains up to 2 micrograms of fluciclovine, 335 MBq to 8,200 MBq (9 mCi to 221 mCi) fluciclovine F 18 at calibration time and date, and 20 mg trisodium citrate in water for injection. The solution also contains hydrochloric acid, sodium hydroxide and has a pH between 4 and 6.</paragraph>
                     </text>
                     <effectiveTime value="20210528"/>
                     <component>
                        <observationMedia ID="mm01">
                           <text>Structural Formula
</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="axu00-0004-01.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s27">
                     <id root="2f9c7d6f-7f2a-f9dd-e063-6294a90abf59"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>11.2 Physical Characteristics</title>
                     <text>
                        <paragraph>Fluorine 18 (F 18) is a cyclotron produced radionuclide that decays by positron emission (ß+ decay, 96.7%) and orbital electron capture (3.3%) to stable oxygen 18 with a physical half-life of 109.7 minutes. The positron can undergo annihilation with an electron to produce two gamma rays; the energy of each gamma ray is 511 keV (
 
  <linkHtml href="#t2">Table 2</linkHtml>).

 </paragraph>
                        <table ID="t2" width="100%">
                           <caption>Table 2: Principal Radiation Produced from Decay of Fluorine 18 Radiation</caption>
                           <col width="23.067%" align="left"/>
                           <col width="38.467%" align="left"/>
                           <col width="38.467%" align="left"/>
                           <tbody>
                              <tr>
                                 <td align="left" styleCode="Toprule Botrule Lrule Rrule" valign="top"/>
                                 <td align="center" styleCode="Toprule Botrule Rrule" valign="top">
                                    <content styleCode="bold">Energy (keV)</content>
                                 </td>
                                 <td align="center" styleCode="Toprule Botrule Rrule" valign="top">
                                    <content styleCode="bold">Abundance (%)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="middle">Positron</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="middle">249.8</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="middle">96.7</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="middle">Gamma</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="middle">511.0</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="middle">193.5</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20210528"/>
                  </section>
               </component>
               <component>
                  <section ID="s28">
                     <id root="2f9c7d6f-7f2b-f9dd-e063-6294a90abf59"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>11.3 External Radiation</title>
                     <text>
                        <paragraph>The point source air-kerma coefficient for F 18 is 3.75 x 10
 
  <sup>-17</sup>Gy m
 
  <sup>2</sup>/(Bq s). The first half-value thickness of lead (Pb) for F 18 gamma rays is approximately 6 mm. The relative reduction of radiation emitted by F 18 that results from various thicknesses of lead shielding is shown in
 
  <linkHtml href="#t3">Table 3</linkHtml>. The use of 8 cm of Pb will decrease the radiation transmission (i.e., exposure) by a factor of about 10,000.

 </paragraph>
                        <table ID="t3" width="100%">
                           <caption>Table 3: Radiation Attenuation of 511 keV Gamma Rays by Lead Shielding</caption>
                           <col width="49.200%" align="left"/>
                           <col width="50.800%" align="left"/>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode="Toprule Botrule Lrule Rrule" valign="top">
                                    <content styleCode="bold">Shield Thickness cm of Lead (Pb)</content>
                                 </td>
                                 <td align="center" styleCode="Toprule Botrule Rrule" valign="top">
                                    <content styleCode="bold">Coefficient of Attenuation</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Botrule Lrule Rrule" valign="middle">0.6</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="middle">0.5</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Botrule Lrule Rrule" valign="top">2</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">0.1</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Botrule Lrule Rrule" valign="top">4</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">0.01</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Botrule Lrule Rrule" valign="top">6</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">0.001</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Botrule Lrule Rrule" valign="top">8</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">0.0001</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20210528"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s29">
               <id root="2f9c7d6f-7f2c-f9dd-e063-6294a90abf59"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20210528"/>
               <component>
                  <section ID="s30">
                     <id root="2f9c7d6f-7f2d-f9dd-e063-6294a90abf59"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of action</title>
                     <text>
                        <paragraph>Fluciclovine F 18 is a synthetic amino acid transported across mammalian cell membranes by amino acid transporters, such as LAT-1 and ASCT2, which are upregulated in prostate cancer cells. Fluciclovine F 18 is taken up to a greater extent in prostate cancer cells compared with surrounding normal tissues.</paragraph>
                     </text>
                     <effectiveTime value="20210528"/>
                  </section>
               </component>
               <component>
                  <section ID="s31">
                     <id root="2f9c7d6f-7f2e-f9dd-e063-6294a90abf59"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>Following intravenous administration, the tumor-to-normal tissue contrast is highest between 4 and 10 minutes after injection, with a 61% reduction in mean tumor uptake at 90 minutes after injection.</paragraph>
                     </text>
                     <effectiveTime value="20210528"/>
                  </section>
               </component>
               <component>
                  <section ID="s32">
                     <id root="2f9c7d6f-7f2f-f9dd-e063-6294a90abf59"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <effectiveTime value="20210528"/>
                     <component>
                        <section ID="s33">
                           <id root="2f9c7d6f-7f30-f9dd-e063-6294a90abf59"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Distribution</content>
                              </paragraph>
                              <paragraph>Following intravenous administration, fluciclovine F 18 distributes to the liver (14% of administered activity), pancreas (3%), lung (7%), red bone marrow (12%) and myocardium (4%). With increasing time, fluciclovine F 18 distributes to skeletal muscle.</paragraph>
                           </text>
                           <effectiveTime value="20210528"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s34">
                           <id root="2f9c7d6f-7f31-f9dd-e063-6294a90abf59"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Excretion</content>
                              </paragraph>
                              <paragraph>Across the first four hours post-injection, 3% of administered radioactivity was excreted in the urine. Across the first 24 hours post-injection, 5% of administered radioactivity was excreted in the urine.</paragraph>
                           </text>
                           <effectiveTime value="20210528"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s35">
               <id root="2f9c7d6f-7f32-f9dd-e063-6294a90abf59"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20210528"/>
               <component>
                  <section ID="s36">
                     <id root="2f9c7d6f-7f33-f9dd-e063-6294a90abf59"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <effectiveTime value="20210528"/>
                     <component>
                        <section ID="s37">
                           <id root="2f9c7d6f-7f34-f9dd-e063-6294a90abf59"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Carcinogenesis</content>
                              </paragraph>
                              <paragraph>No long term studies in animals have been performed to evaluate the carcinogenic potential of fluciclovine.</paragraph>
                           </text>
                           <effectiveTime value="20210528"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s38">
                           <id root="2f9c7d6f-7f35-f9dd-e063-6294a90abf59"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Mutagenesis</content>
                              </paragraph>
                              <paragraph>Fluciclovine was not mutagenic
 
  <content styleCode="italics">in vitro</content>in reverse mutation assay in bacterial cells and in chromosome aberration test in cultured mammalian cells, and was negative in an
 
  <content styleCode="italics">in vivo</content>clastogenicity assay in rats after intravenous injection of doses up to 43 mcg/kg. However, fluciclovine F 18 has the potential to be mutagenic because of the F 18 radioisotope.

 </paragraph>
                           </text>
                           <effectiveTime value="20210528"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s39">
                           <id root="2f9c7d6f-7f36-f9dd-e063-6294a90abf59"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Impairment of Fertility</content>
                              </paragraph>
                              <paragraph>No studies in animals have been performed to evaluate potential impairment of fertility in males or females.</paragraph>
                           </text>
                           <effectiveTime value="20210528"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s40">
               <id root="2f9c7d6f-7f37-f9dd-e063-6294a90abf59"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph>The safety and efficacy of Axumin were evaluated in two studies (Study 1 and Study 2) in men with suspected recurrence of prostate cancer based on rising PSA levels following radical prostatectomy and/or radiotherapy.</paragraph>
                  <paragraph>Study 1 evaluated 105 Axumin scans in comparison to histopathology obtained by biopsy of the prostate bed and biopsies of lesions suspicious by imaging. PET/CT imaging generally included the abdomen and pelvic regions. The Axumin images were originally read by on-site readers. The images were subsequently read by three blinded independent readers.
 
  <linkHtml href="#t4">Table 4</linkHtml>shows the performance of Axumin in the detection of recurrence in each patient scan and, specifically, within the prostatic bed and extra-prostatic regions, respectively. The results of the independent read were generally consistent with one another and confirmed the results of the on-site reads.

 </paragraph>
                  <table ID="t4" width="100%" styleCode="Noautorules">
                     <caption>Table 4: Performance of Axumin in Patients with Biochemically Suspected Recurrent Prostate Cancer, at the Patient Level and at the Prostate Bed and Extraprostatic Region Levels</caption>
                     <col width="25.000%" align="left"/>
                     <col width="25.000%" align="left"/>
                     <col width="25.000%" align="left"/>
                     <col width="25.000%" align="left"/>
                     <tfoot>
                        <tr>
                           <td colspan="4" align="left" valign="top">
                              <paragraph styleCode="footnote">N = number of patient scans evaluated</paragraph>
                           </td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr>
                           <td align="left" styleCode="Botrule Rrule" valign="top"/>
                           <td align="center" styleCode="Botrule Rrule" valign="top">Reader 1</td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">Reader 2</td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">Reader 3</td>
                        </tr>
                        <tr>
                           <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Patient</td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">N = 104</td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">N = 105</td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">N = 99</td>
                        </tr>
                        <tr>
                           <td align="left" styleCode="Botrule Lrule Rrule" valign="top">   True Positive</td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">75</td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">72</td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">63</td>
                        </tr>
                        <tr>
                           <td align="left" styleCode="Botrule Lrule Rrule" valign="top">   False Positive</td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">24</td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">23</td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">13</td>
                        </tr>
                        <tr>
                           <td align="left" styleCode="Botrule Lrule Rrule" valign="top">   True Negative</td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">5</td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">7</td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">15</td>
                        </tr>
                        <tr>
                           <td align="left" styleCode="Botrule Lrule Rrule" valign="top">   False Negative</td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">0</td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">3</td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">8</td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" styleCode="Botrule Lrule Rrule" valign="top">   </td>
                        </tr>
                        <tr>
                           <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Prostate Bed</td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">N = 98</td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">N = 97</td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">N = 96</td>
                        </tr>
                        <tr>
                           <td align="left" styleCode="Botrule Lrule Rrule" valign="top">   True Positive</td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">58</td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">56</td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">47</td>
                        </tr>
                        <tr>
                           <td align="left" styleCode="Botrule Lrule Rrule" valign="top">   False Positive</td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">29</td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">26</td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">15</td>
                        </tr>
                        <tr>
                           <td align="left" styleCode="Botrule Lrule Rrule" valign="top">   True Negative</td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">10</td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">12</td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">24</td>
                        </tr>
                        <tr>
                           <td align="left" styleCode="Botrule Lrule Rrule" valign="top">   False Negative</td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">1</td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">3</td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">10</td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" styleCode="Botrule Lrule Rrule" valign="middle">   </td>
                        </tr>
                        <tr>
                           <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Extraprostatic</td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">N = 28</td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">N = 28</td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">N = 25</td>
                        </tr>
                        <tr>
                           <td align="left" styleCode="Botrule Lrule Rrule" valign="top">   True Positive</td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">25</td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">26</td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">22</td>
                        </tr>
                        <tr>
                           <td align="left" styleCode="Botrule Lrule Rrule" valign="top">   False Positive</td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">2</td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">2</td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">2</td>
                        </tr>
                        <tr>
                           <td align="left" styleCode="Botrule Lrule Rrule" valign="top">   True Negative</td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">0</td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">0</td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">0</td>
                        </tr>
                        <tr>
                           <td align="left" styleCode="Botrule Lrule Rrule" valign="top">   False Negative</td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">1</td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">0</td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">1</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>The detection rate of Axumin seems to be affected by PSA levels
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#s12">5.1</linkHtml>)]
 
  </content>. In general, patients with negative scans had lower PSA values than those with positive scans.  The detection rate (number with positive scans/total scanned) for patients with a PSA value of less than or equal to 1.78 ng/mL (1st PSA quartile) was 15/25, of which 11 were histologically confirmed as positive. In the remaining three PSA quartiles, the detection rate was 71/74, of which 58 were histologically confirmed. Among the 25 patients in the first PSA quartile, there were 4 false positive scans and 1 false negative scan.  For the 74 patients with PSA levels greater than1.78 ng/mL, there were 13 false positive scans and no false negative scans.

 </paragraph>
                  <paragraph>Study 2 evaluated the concordance between 96 Axumin and C11 choline scans in patients with median PSA value of 1.44 ng/mL (interquartile range = 0.78 ng/mL to 2.8 ng/mL). The C 11 choline scans were read by on-site readers. The Axumin scans were read by the same three blinded independent readers used for Study 1. The agreement values between the Axumin and C11 choline reads were 61%, 67% and 77%, respectively.</paragraph>
               </text>
               <effectiveTime value="20210528"/>
            </section>
         </component>
         <component>
            <section ID="s41">
               <id root="2f9c7d6f-7f38-f9dd-e063-6294a90abf59"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <effectiveTime value="20210528"/>
               <component>
                  <section ID="s42">
                     <id root="2f9c7d6f-7f39-f9dd-e063-6294a90abf59"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>16.1 How Supplied</title>
                     <text>
                        <paragraph>Axumin is supplied as a clear, colorless injection in a 30 mL or 50 mL multiple-dose glass vial containing approximately 26 mL solution of 335 MBq/mL to 8,200 MBq/mL (9 mCi/mL to 221 mCi/mL) fluciclovine F 18 at calibration time and date.</paragraph>
                        <paragraph>30 mL sterile multiple-dose vial: NDC 69932-001-30</paragraph>
                        <paragraph>50 mL sterile multiple-dose vial: NDC 69932-001-50</paragraph>
                     </text>
                     <effectiveTime value="20210528"/>
                  </section>
               </component>
               <component>
                  <section ID="s43">
                     <id root="2f9c7d6f-7f3a-f9dd-e063-6294a90abf59"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <title>16.2 Storage and Handling</title>
                     <text>
                        <paragraph>Store Axumin at controlled room temperature (USP) 20°C to 25°C (68°F to 77°F). Axumin does not contain a preservative. Store Axumin within the original container in radiation shielding. Do not use Axumin more than 10 hours after end of synthesis and dispose of in accordance with institutional guidelines.</paragraph>
                        <paragraph>This preparation is approved for use by persons under license by the Nuclear Regulatory Commission or the relevant regulatory authority of an Agreement State.</paragraph>
                     </text>
                     <effectiveTime value="20210528"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s44">
               <id root="2f9c7d6f-7f3b-f9dd-e063-6294a90abf59"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <list listType="unordered" styleCode="Disc">
                     <item>Instruct patients to avoid significant exercise for at least a day before the PET scan.</item>
                     <item>Instruct patients not to eat or drink for at least 4 hours before the PET scan (other than sips of water for taking medications).</item>
                     <item>Instruct patients to try to urinate approximately 30 minutes to 60 minutes prior to planned start time of the PET scan and to avoid further urination until after the scan has been completed.</item>
                  </list>
                  <paragraph>Marketed by Blue Earth Diagnostics Ltd. Oxford, UK OX4 4GA 
  <br/>  Axumin
 
  <sup>®</sup>is a registered trademark of Blue Earth Diagnostics Ltd. 
  <br/>  © 2022 Blue Earth Diagnostics Ltd – all rights reserved.

 </paragraph>
                  <paragraph>
                     <renderMultiMedia ID="f02" referencedObject="mm02"/>
                  </paragraph>
               </text>
               <effectiveTime value="20220720"/>
               <component>
                  <observationMedia ID="mm02">
                     <text>Blue Earth Diagnostics Logo
</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="axu00-0004-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="p1">
               <id root="2f9c7d6f-7f3c-f9dd-e063-6294a90abf59"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">Principal Display Panel - 30 mL Multiple-Dose Vial Label</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics">Sterile</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Axumin™</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics">Non-pyrogenic</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">335 MBq/mL to 8,200 MBq/mL (9 mCi/mL to 
   <br/>  221 mCi/mL) at End of Synthesis (EOS)
  </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Diagnostic - For Intravenous Use Only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="italics">Expires 10 hours after EOS</content>
                     </content>
                  </paragraph>
                  <paragraph>Batch #: ________________________________</paragraph>
                  <paragraph>EOS Date: __________ EOS Time: __________</paragraph>
                  <paragraph>Activity @ EOS: ___________________ mCi</paragraph>
                  <paragraph>Concentration: ___________________ mCi/mL</paragraph>
                  <paragraph>Volume: ___________________ mL</paragraph>
                  <paragraph>Exp. Date: __________ Exp. Time: __________</paragraph>
                  <renderMultiMedia ID="f03" referencedObject="mm03"/>
               </text>
               <effectiveTime value="20200831"/>
               <component>
                  <observationMedia ID="mm03">
                     <text>Principal Display Panel - 30 mL Multiple-Dose Vial Label
</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="axu00-0004-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>